Journal of Liver Cancer

Review Articles

Second-line antidiabetic drugs: friend or foe of the liver: Jiwon Yang, Gunho Kim, Ju Hyun Shim, Jihyun An; J Liver Cancer. 2025;25(2):187-203. Published online June 26, 2025; DOI: https://doi.org/10.17998/jlc.2025.06.25

1,392 Views
74 Downloads
1 Citation

Diabetes mellitus is a cardiometabolic risk factor associated with the development of various comorbidities and malignancies. It has a bidirectional relationship with chronic liver disease, promoting hepatic inflammation and fibrosis, which can ultimately progress to advanced liver diseases such as cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Therefore, the importance of antidiabetic treatment has been increasingly emphasized as a strategy for preventing liver-related diseases in diabetic patients. Metformin, a first-line antidiabetic agent, has been shown to be effective in improving hepatic steatosis and preventing progression to advanced liver disease. Recently updated international guidelines recommend the use of metformin as a chemopreventive agent for HCC in diabetic patients, albeit with a weak recommendation. Meanwhile, as metformin alone is often insufficient for blood glucose control and concurrent metabolic comorbidities are increasingly prevalent, new second-line antidiabetic agents have been developed: glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors. These novel antidiabetic agents have demonstrated cardiovascular benefits, and protective effects on liver-related outcomes and mortality in previous studies. However, due to the limited number of studies and the variability in study populations, their effects remain inconsistent across different studies. Furthermore, there are no established therapeutic guidelines for diabetic patients with liver disease. Therefore, this review aims to examine the association between the use of novel second-line antidiabetic agents and the risk of liver-related outcomes and mortality in this population.

Citations

Citations to this article as recorded by

Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review
Mario Romeo, Fiammetta Di Nardo, Carmine Napolitano, Claudio Basile, Carlo Palma, Paolo Vaia, Marcello Dallio, Alessandro Federico
Diabetology.2025; 6(8): 79. CrossRef

Prognostic Significance of Preoperative Controlling Nutritional Status Score in Patients Who Underwent Hepatic Resection for Hepatocellular Carcinoma: Bum-Soo Kim; J Liver Cancer. 2020;20(2):106-112. Published online September 30, 2020; DOI: https://doi.org/10.17998/jlc.20.2.106

5,544 Views
98 Downloads
4 Citations

Abstract PDF

Malnutrition is common in patients with hepatocellualar carcinoma (HCC), and is associated with postoperative complications after hepatectomy, and also increased mortality. However, there is currently no recommendation for assessment of nutritional status in HCC patients. The controlling nutritional status (CONUT) score has been correlated with prognosis in gastrointestinal cancer patients, but there are few reports on the prognostic significance of the CONUT score in patients who underwent hepatectomy for HCC. Existing results show that patients with high CONUT scores who undergo hepatectomy for HCC have poorer survival outcomes, and experience more complications than other patients. In this paper, we review the literature, and reveal that patients who underwent hepatectomy for HCC with high preoperative CONUT scores had poorer outcomes than those with low CONUT scores. Therefore, we conclude that a preoperative CONUT score may be useful for prognostic prediction in patients with HCC undergoing curative hepatectomy.

Citations

Citations to this article as recorded by

Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy
Seulah Park, Go-Won Choi, Inhyuck Lee, Younsoo Seo, Yoon Soo Chae, Won-Gun Yun, Youngmin Han, Hye-Sol Jung, Wooil Kwon, Joon Seong Park, Jin-Young Jang, Young Jae Cho
Nutrients.2025; 17(4): 647. CrossRef
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis
Elsa Vitale, Lorenza Maistrello, Alessandro Rizzo, Oronzo Brunetti, Raffaella Massafra, Veronica Mollica, Francesco Massari, Matteo Santoni
Immunotherapy.2025; 17(4): 269. CrossRef
The CRP–albumin–lymphocyte index provides enhanced prognostic value in liver cancer compared to the TNM staging system
Hong Zhao, Bing Yin, Xiang-Rui Li, Xiao-Yue Liu, Zhao-Ting Bu, Han-Ping Shi
Scientific Reports.2025;[Epub] CrossRef
Demographic, clinical and psychological predictors of malnutrition among people with liver cancer
Yumi Kim, Sung Reul Kim, Kyounghae Kim, Su Jong Yu
European Journal of Oncology Nursing.2024; 68: 102497. CrossRef

Liver Transplantation in Mixed Hepatocellular Carcinoma and Cholangiocarcinoma: Jong Man Kim; J Liver Cancer. 2019;19(2):85-90. Published online September 30, 2019; DOI: https://doi.org/10.17998/jlc.19.2.85

6,008 Views
108 Downloads
2 Citations

Abstract PDF

Mixed hepatocellular carcinoma and cholangiocarcinoma (HCC-CC) are rare tumors, and the risk factors associated with them are not well understood yet. Moreover, the diagnosis of mixed HCC-CC can be complicated due to the difficulty in distinguishing mixed HCC-CC from HCC and intrahepatic CCC on radiological images. Serum tumor markers are useful when the radiological images are inconclusive. It remains unclear whether the prognosis of mixed HCC-CC differs from that of HCC. However, several studies have reported that the tumor recurrence and patient survival rates of mixed HCC-CC were similar to those of HCC after liver transplantation (LT) and liver resection. In this paper, we report that LT in patients with mixed HCC-CC achieves outcomes which are similar to those seen in LT for HCC. Therefore, the diagnosis of mixed HCC-CC should not be considered as a contraindication for LT.

Citations

Citations to this article as recorded by

Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study
Jongman Kim, Dong-Jin Joo, Shin Hwang, Jeong-Moo Lee, Je-Ho Ryu, Yang-Won Nah, Dong-Sik Kim, Doo-Jin Kim, Young-Kyoung You, Hee-Chul Yu
World Journal of Gastrointestinal Surgery.2023; 15(7): 1340. CrossRef
The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation
Safak Gül-Klein, Paulina Schmitz, Wenzel Schöning, Robert Öllinger, Georg Lurje, Sven Jonas, Deniz Uluk, Uwe Pelzer, Frank Tacke, Moritz Schmelzle, Johann Pratschke, Ramin Raul Ossami Saidy, Dennis Eurich
Cancers.2022; 14(12): 2890. CrossRef

First
Prev
Page of 1
Next
Last

Search